Emyria Limited Expands Perth Clinic Amid Rising Demand and National Rollout Strategy.

Emyria Limited (ASX: EMD), a leader in innovative mental health treatments, is expanding its Perth Clinic to meet surging patient demand and support its capital-light national rollout. Following its landmark agreement with Medibank Private (ASX: MPL), the first Medibank-funded patients have commenced PTSD therapy—marking Australia’s first private health insurance coverage for psychedelic-assisted care. This milestone validates Emyria’s Empax platform, creating a scalable reimbursement pathway that reduces patient costs while underpinning recurring revenues.

Demand is accelerating rapidly, with August dosing sessions forecast to exceed the previous four months combined, prompting workforce recruitment and facility upgrades in Perth. In parallel, Emyria is progressing its first interstate clinic in Brisbane through a partnership with Avive Health, leveraging existing hospital infrastructure for efficient expansion. With mental health conditions such as PTSD affecting one in eleven Australians, Emyria is executing a national strategy to expand access, partner with insurers, and build a scalable, evidence-backed network of clinics.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com